Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
-
REGULATORY MHLW Warns against Hoarding on 17 APIs as Hitachi Fire Stirs Supply Worries
December 8, 2021
-
BUSINESS EU Panel Backs Tocilizumab for Severe COVID-19: Chugai
December 8, 2021
-
BUSINESS Horizon Plants Flag in Japan Soil to Gear Up for Thyroid Eye Disease Trial
December 7, 2021
-
REGULATORY BMS’ Second CAR-T Therapy Ide-Cel in Line for Approval in January
December 7, 2021
-
BUSINESS Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
-
REGULATORY Panel OKs Outline of Emergency Approval System Based on “Presumed” Efficacy
December 6, 2021
-
REGULATORY MOF Panel’s Budget Proposal Pushes Macroeconomic Indexing, No Adjustment Rate
December 6, 2021
-
BUSINESS MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
-
REGULATORY Average NHI-Market Price Gap of Listed Drugs at 7.6%: MHLW
December 3, 2021
-
REGULATORY Chuikyo Members Call for Restrictions in Re-Pricing Exclusions from Spillover Rule
December 2, 2021
-
BUSINESS Blaze at Hitachi Logistic Center Could Add to Drug Supply Woes
December 1, 2021
-
REGULATORY Japan Confirms 1st Case of Omicron Variant: MHLW
December 1, 2021
-
REGULATORY Alzheimer’s Drugs in Mind, MHLW to Float New Rule for Potential Super Big Sellers
November 30, 2021
-
BUSINESS Takeda’s GI Biz Poised for Growth with 3 Products Now in Its Lineup
November 29, 2021
-
REGULATORY Japan Approves Jardiance for Heart Failure, Label Expansions for Opdivo and Keytruda
November 26, 2021
-
REGULATORY Pharma Pushes 2% Adjustment Rate Plus Certain Range in 2022 Drug Price Revision
November 26, 2021
-
REGULATORY Sanofi’s Praluent to Be Taken Off Japan NHI Price List Next Spring
November 26, 2021
-
REGULATORY LDP Health Panel Chief Vows to Push Development of Japan-Made Vaccines and Drugs
November 25, 2021
-
BUSINESS Top 3 Japan Generic Makers Face Uphill Struggle Overseas in April-September: Jiho Tally
November 25, 2021
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…